| MA |
Report |
2Q26 net revenue |
BEAT |
pred ~$9.18B vs. cons $9.07B |
MEDIUM |
| MA |
Report |
2Q26 adjusted EPS |
BEAT |
pred ~$4.88 vs. cons $4.77 |
MEDIUM |
| MA |
Report |
2Q26 VAS currency-neutral revenue growth |
BEAT |
pred ~19% vs. cons 17% |
MEDIUM |
| MA |
Guide |
FY26 currency-neutral net-revenue growth |
LOWER |
guide ~11.5% vs. cons 12.0% (FY26) |
MEDIUM |
| MA |
Guide |
FY26 adjusted operating-expense growth, currency-neutral |
UNCHANGED |
guide ~11.0% vs. cons 11.0% (FY26) |
MEDIUM |
| MA |
Guide |
2H26 cross-border-travel recovery assumption |
LOWER |
guide ~6% growth vs. cons 9% growth (2H26) |
LOW |
| MA |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.8% |
— |
MEDIUM |
| MA |
Return |
5-day cumulative residual |
-4.5% (FOLLOW-THROUGH) |
A ~2% EPS beat and ~1% revenue beat are likely outweighed by ~50 bps of implicit FY26 revenue-growth de-risking: July geopolitical/travel conditions weaken the assumed 2H cross-border recovery, pulling FY26 and FY27 revenue/EPS estimates lower despite strong VAS. Pred ~11.5% FY26 revenue growth vs. cons 12.0%; pred ~$20.40 FY26 EPS vs. cons ~$20.75. |
MEDIUM |